Biovian has unveiled plans to make an investment of US$54 million (€50 million) in expanding its manufacturing facility in Turku, Finland.
The new facility, which covers an area of 6,400 square metres (69,000 square feet), will feature cutting-edge machinery and advanced technologies to facilitate the entire process of creating, manufacturing, and testing Advanced Therapy Medicinal Products (ATMP), including therapies like adenoviral and adeno-associated viral (AAV) treatments.
When combined with current manufacturing site, the new facility will expand the overall area to 11,500 square metres (123,800 square feet).
Additionally, the facility will include specialised cleanroom sections, ranging from Class A to D, dedicated to the production of bulk drug substances and the final manufacturing of drug products.
The new space serves as a valuable addition to the existing manufacturing facilities in the region, providing with the capability to embark on larger-scale viral vector and microbial protein projects.
As the new facility becomes operational, the existing capacity will be repurposed into innovative microbial protein suites.
This expansion will not only enhance the capacity for viral vector production but also provide increased capabilities and adaptability in microbial protein manufacturing.
The new facility is projected to become fully operational by 2025 and generate around 100 employment opportunities within the region.
Type New Construction
Budget US$54 million (€50 million)